Unlock stock picks and a broker-level newsfeed that powers Wall Street.
NasdaqGS - Nasdaq Real Time Price USD

TherapeuticsMD, Inc. (TXMD)

Compare
0.9800
+0.0550
+(5.95%)
At close: April 1 at 4:00:00 PM EDT
1.0100
+0.03
+(3.06%)
After hours: April 1 at 7:51:23 PM EDT
Loading Chart for TXMD
  • Previous Close 0.9250
  • Open 0.9200
  • Bid 0.9179 x 100
  • Ask 0.9999 x 100
  • Day's Range 0.9200 - 0.9800
  • 52 Week Range 0.7000 - 2.4400
  • Volume 26,119
  • Avg. Volume 448,665
  • Market Cap (intraday) 11.302M
  • Beta (5Y Monthly) 1.17
  • PE Ratio (TTM) --
  • EPS (TTM) -0.2000
  • Earnings Date May 8, 2025 - May 12, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brand names. The company sells its prescription pharmaceutical products and prenatal vitamin products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.

www.therapeuticsmd.com

1

Full Time Employees

December 31

Fiscal Year Ends

Recent News: TXMD

View More

Performance Overview: TXMD

Trailing total returns as of 4/1/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TXMD
13.95%
S&P 500 (^GSPC)
4.23%

1-Year Return

TXMD
57.76%
S&P 500 (^GSPC)
7.42%

3-Year Return

TXMD
94.84%
S&P 500 (^GSPC)
23.92%

5-Year Return

TXMD
98.04%
S&P 500 (^GSPC)
128.01%

Compare To: TXMD

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: TXMD

View More

Valuation Measures

Annual
As of 4/1/2025
  • Market Cap

    11.30M

  • Enterprise Value

    13.42M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.42

  • Price/Book (mrq)

    0.41

  • Enterprise Value/Revenue

    7.62

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -207.77%

  • Return on Assets (ttm)

    -6.65%

  • Return on Equity (ttm)

    -14.39%

  • Revenue (ttm)

    1.6M

  • Net Income Avi to Common (ttm)

    -3.97M

  • Diluted EPS (ttm)

    -0.2000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.05M

  • Total Debt/Equity (mrq)

    27.31%

  • Levered Free Cash Flow (ttm)

    -10.92M

Research Analysis: TXMD

View More

Company Insights: TXMD

Research Reports: TXMD

View More

People Also Watch